Author

Griet Compernolle 1

1 KU Leuven,Leuven,Belgium

EVALUATING EFFICACY, SAFETY AND PHARMACOKINETICS AFTER SWITCHING FROM INFLIXIMAB ORIGINATOR TO BIOSIMILAR CT-P13: RESULTS FROM A LARGE TERTIARY REFERRAL CENTER

Michiel Bronswijk, Annick Moens, Matthias Lenfant, Griet Compernolle, Gert Van Assche, Severine Vermeire, Ann Gils, Marc Ferrante

INDUCTION AND EARLY MAINTENANCE VEDOLIZUMAB TROUGH LEVELS PREDICT MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE

Jurij Hanzel, Nejc Sever, Griet Compernolle, Sophie Tops, Ivan Ferkolj, Borut Stabuc, Natasa Smrekar, Matic Koželj, Tina Kurent, Gregor Novak, Ann Gils, David Drobne

INFLIXIMAB DOSE DOUBLING IS EFFECTIVE FOR OPTIMIZING TROUGH CONCENTRATIONS AND REGAINING CLINICAL RESPONSE IN PATIENTS WITH CROHN?S DISEASE

Erwin Dreesen, Vera Ballet, Griet Compernolle, Gert Van Assche, Marc Ferrante, Severine Vermeire, Ann Gils

RANDOMISED CONTROLLED TRIAL OF DRUG LEVEL VERSUS CLINICALLY BASED DOSING OF INFLIXIMAB MAINTENANCE THERAPY IN IBD: FINAL RESULTS OF THE TAXIT STUDY

Niels Vande Casteele, Ann Gils, Vera Ballet, Griet Compernolle, Miet Peeters, Kristel Van Steen, Steven Simoens, Marc Ferrante, Gert Van Assche, Severine Vermeire, Paul Rutgeerts

VEDOLIZUMAB EXPOSURE CORRELATES WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC OUTCOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Ann Gils, Erwin Dreesen, Griet Compernolle, Miet Peeters, Els Brouwers, Vera Ballet, Maja Noman, Marc Ferrante, Gert Van Assche, Severine Vermeire

Item 1 - 5 / 9
1